Brief: Alzamend Receives Pre-IND Response From FDA For AL001 Treatment Of Bipolar Disorder, MDD, PTSD

Alzamend Neuro

18/07/2022 13:50

July 18 (Reuters) - Alzamend Neuro Inc  ALZN.O :
    * ALZAMEND NEURO RECEIVES POSITIVE PRE-IND RESPONSE FROM FDA
FOR
AL001 TREATMENT OF BIPOLAR DISORDER, MAJOR DEPRESSIVE DISORDER
AND POST-TRAUMATIC STRESS DISORDER
    * ALZAMEND NEURO INC - TOPLINE DATA EXPECTED IN DECEMBER
2022 FROM
PHASE IIA MULTIPLE ASCENDING DOSE CLINICAL TRIAL FOR AL001
    * ALZAMEND NEURO INC - FULL DATA FROM PHASE I FIRST-IN-HUMAN
STUDY
DEMONSTRATED AL001 IN PLASMA IS BIOEQUIVALENT TO MARKETED
LITHIUM CARBONATE PRODUCT

Source text for Eikon:  ID:nBwbXxLMta 
Further company coverage:  ALZN.O 

 ((Reuters.Briefs@thomsonreuters.com;))